Brief: Abvc Biopharma Provides Updates On Adhd Phase Iib Clinical Study
23/08/2023 13:32
Aug 23 (Reuters) -
* ABVC BIOPHARMA PROVIDES UPDATES ON ADHD PHASE IIB CLINICAL
STUDY
* ABVC BIOPHARMA INC - FOR VITARGUS, CO INTENDS TO CONDUCT
GLOBAL
CLINICAL TRIALS THROUGH PHASE III
* ABVC BIOPHARMA INC - 60 SUBJECTS HAD BEEN ENROLLED AND 53
HAD
COMPLETED EIGHT-WEEK STUDY FOR CO'S ADHD PHASE IIB CLINICAL
STUDY
* ABVC BIOPHARMA INC - PHASE IIB CLINICAL STUDY CONTINUES
PHASE
IIA CLINICAL STUDY OF ABV-1505
Source text for Eikon: ID:nGNX1TYLrn
Further company coverage: ABVC.O
((reuters.briefs@thomsonreuters.com;))
Recent news on ABVC Biopharma
See all newsBrief: ABVC Biopharma - Quarterly Period Ended September, 2025 Financial Statements Should Not Be Relied Upon
Brief: Abvc Biopharma Inc Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: ABVC Biopharma Concluded That Financial Statements For FY Ended Dec 31, 2023 Should No Longer Be Relied Upon Due To Errors In Financial Statements
Brief: ABVC Biopharma Inc On March 5, Leeds Chow Resigns As CFO Of Abvc Biopharma
Brief: ABVC Biopharma Secures $200,000 In First Cash Licensing Payment From Oncology Products Partner